Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 2:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 241 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Normal Saline 10 mL Injection Clear all
Terminated Phase 4 Interventional Results available

Sciatic Block in Contralateral Limb Phantom and Residual Limb Pain

NCT05046639
View directory record Official record
Conditions
Pain, Amputation
Interventions
10 mL 2% lidocaine, 10 mL preservative free saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Not applicable Interventional Results available

Effect of Paracervical Block on Post Operative Pain in Laparoscopic Gynecologic Surgery

NCT01534416
View directory record Official record
Conditions
Postoperative Pain, Paracervical Block, Laparoscopic Gynecologic Surgery
Interventions
Bupivacaine, Normal Saline
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress

NCT01370265
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Regadenoson, Adenosine, N-13 ammonia
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 4 Interventional Results available

Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis

NCT03991936
View directory record Official record
Conditions
Nail Psoriasis, Nail Diseases
Interventions
Placebos, Triamcinolone Acetonide 2.5 mg/mL, Triamcinolone Acetonide 5.0 mg/mL, Triamcinolone Acetonide 7.5 mg/mL, Triamcinolone Acetonide 10 mg/mL
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 9, 2026, 2:02 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

NCT07167693
View directory record Official record
Conditions
Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions
Arginine hydrochloride, Sodium Chloride 0.9%
Drug
Lead sponsor
David K Carroll
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study

NCT03298867
View directory record Official record
Conditions
Thyroid Eye Disease, Graves' Orbitopathy
Interventions
Teprotumumab, Placebo
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
9
States / cities
Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Sep 9, 2026, 2:02 AM EDT
Recruiting Phase 1 Interventional

Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM

NCT04991870
View directory record Official record
Conditions
Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma, Supratentorial Gliosarcoma
Interventions
Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Resection
Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 4 Interventional

Optimal Timing of Intercostal Nerve Blocks During Video-Assisted Thoracic Surgeries

NCT02980835
View directory record Official record
Conditions
Video-Assisted Thoracic Surgery, Video-Assisted Thoracoscopic Surgery
Interventions
Normal Saline, Ropivacaine, Epinephrine, Dexamethasone
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination

NCT04722003
View directory record Official record
Conditions
Gonorrhoea
Interventions
Meningococcal Group B Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2012 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

NCT04228783
View directory record Official record
Conditions
Ebola
Interventions
Ad26.ZEBOV, MVA-BN-Filo, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
974 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
7
States / cities
Mobile, Alabama • Tempe, Arizona • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Botox on Reducing Rest Tremor in Parkinson's Disease

NCT03301272
View directory record Official record
Conditions
Parkinson Disease
Interventions
Onabotulinumtoxin A Injection, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 16, 2020 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

Phase 3, Sciatic Nerve Block With EXPAREL for Subjects Undergoing Bunionectomy

NCT05157841
View directory record Official record
Conditions
Bunionectomy, Hallux Valgus
Interventions
Bupivacaine liposome injectable suspension 266 mg, Bupivacaine HCl, Bupivacaine liposome injectable suspension 133 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
North Little Rock, Arkansas • Pasadena, California • Dayton, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

Anticholinergic vs. Botox Comparison Study

NCT01166438
View directory record Official record
Conditions
Urge Urinary Incontinence, Overactive Bladder
Interventions
Botulinum toxin A (Botox A®), Solifenacin 5mg, Solifenacin 10mg, Trospium chloride
Drug
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
21 Years and older · Female only
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
11
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 4 Interventional Results available

Improvement of Pain Following Robotic Sacrocolpopexy and Rectocele Repair for Pelvic Organ Prolapse

NCT02449915
View directory record Official record
Conditions
Pelvic Organ Prolapse
Interventions
Bupivacaine, Placebo
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 4 Interventional Results available

A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease

NCT00162370
View directory record Official record
Conditions
Coronary Artery Disease, Heart Disease
Interventions
Perflutren Lipid Microsphere Injectable Suspension
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2021 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 4 Interventional Results available

Trial Liposomal Bupivacaine Following Retropubic Suburethral Sling for Stress Urinary Incontinence

NCT02296099
View directory record Official record
Conditions
Urinary Incontinence, Stress
Interventions
liposomal bupivacaine, Placebo
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring

NCT05777174
View directory record Official record
Conditions
Kidney Diseases, Kidney Injury, Kidney Failure
Interventions
MB-102, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
Drug · Device
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
5
States / cities
Chicago, Illinois • Columbus, Ohio • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 9, 2026, 2:02 AM EDT
Completed No phase listed Observational

Comparison of Epidural and TAP Block in Abdominal Surgery

NCT01848951
View directory record Official record
Conditions
Acute Pain, Surgery, Regional Anesthesia
Interventions
Epidural, TAP Block
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 9, 2026, 2:02 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon

NCT03639766
View directory record Official record
Conditions
Raynaud Phenomenon
Interventions
AbobotulinumtoxinA, Saline solution
Drug · Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 9, 2026, 2:02 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of Protein Loading on Measurement of Renal Reserve

NCT07335614
View directory record Official record
Conditions
Glomerular Filtration Rate
Interventions
Lumitrace, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
Device
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 9, 2026, 2:02 AM EDT
Recruiting Phase 2 Interventional

Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain

NCT04930887
View directory record Official record
Conditions
Craniofacial Pain, Migraine, Cluster Headache, Trigeminal Autonomic Cephalgia, Sphenopalatine Ganglion Neuralgia, Paroxysmal Hemicrania
Interventions
Exparel (Bupivacaine Liposome), Saline
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Results available

Metoclopramide Versus Placebo for GJ Placement

NCT03331965
View directory record Official record
Conditions
Radiation Exposure, Enteral Nutrition
Interventions
Metoclopramide 5 MG/ML Injectable Solution, Saline
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 4 Interventional

TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

NCT05002998
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Teprotumumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
Beverly Hills, California • Los Angeles, California • Palo Alto, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 9, 2026, 2:02 AM EDT